Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyPresbyterian Nerve Fiber Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentPresbyterian Health PlanPolicy AHS - M2112

    Nerve Fiber Density Testing

    Customize your policy alerts

    Sign up for Presbyterian Health Plan Policy AHS - M2112 alerts

    Get alerted when Policy AHS - M2112 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of epidermal nerve fiber density measurement from skin biopsy for diagnosing small-fiber neuropathy. Testing is covered only when all four specified clinical, examination, and electrodiagnostic criteria are met; other situations and sweat gland nerve fiber density measurement do not meet coverage criteria.

    Policy Summary
    PayerPresbyterian Health Plan
    PolicyNerve Fiber Density Testing
    Policy CodePolicy N/A
    Change TypeNon-material revision
    Effective DateJun 1, 2026
    Next Review DateN/A
    Key ActionVerify that all four coverage criteria are met before requesting epidermal nerve fiber density measurement for small-fiber neuropathy.
    SourceLink
    POLICY UPDATE CHANGES

    The policy background, guidelines and recommendations, and evidence-based scientific references were updated.

    A New Mexico Medicaid website link was added to the applicable state and federal regulations section.

    4Required coverage conditions

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    7Listed procedure codes
    3 mmBiopsy size
    69Evidence-based references

    Coverage Criteria

    Diagnosis of small-fiber neuropathy

    Covered when ALL of the following are met:

    Small-fiber neuropathy diagnostic criteria

    • Clinical presentation: The individual presents with symptoms of painful sensory neuropathy.
    • No predisposing disorder: There is no history of a disorder known to predispose to painful neuropathy, such as diabetic neuropathy, toxic neuropathy, HIV neuropathy, celiac neuropathy, or inherited neuropathy.
    • No large-fiber findings: Physical examination shows no evidence of findings consistent with large-fiber neuropathy, including reduced or absent muscle-stretch reflexes or reduced proprioception and vibration sensation.
    • Normal electrodiagnostic studies: Electromyography and nerve-conduction studies are normal and show no evidence of large-fiber neuropathy.

    For all situations not described by the specified four-part coverage criteria for diagnosing small-fiber neuropathy, epidermal nerve fiber density measurement from a skin biopsy does not meet coverage criteria.

    Measurement of sweat gland nerve fiber density does not meet coverage criteria.

    Applicable Procedure Codes

    Applicable CPT/HCPCS Procedure CodesCPT
    88313Special stain including interpretation and report; Group II, all other (eg, iron, trichrome), except stain for microorganisms, stains for enzyme constituents, or immunocytochemistry and immunohistochemistry.
    88341Immunohistochemistry or immunocytochemistry, per specimen; each additional single antibody stain procedure (List separately in addition to code for primary procedure).
    88342Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure.
    88344Immunohistochemistry or immunocytochemistry, per specimen; each multiplex antibody stain procedure.
    88346Immunofluorescence, per specimen; initial single antibody stain procedure.
    88350Immunofluorescence, per specimen; each additional single antibody stain procedure (List separately in addition to code for primary procedure).
    88356Morphometric analysis; nerve.

    Coverage Exclusions and Denial Risks

    Denial Risk

    Meet all four coverage conditions

    Epidermal nerve fiber density measurement from a skin biopsy does not meet coverage criteria when any required condition for the diagnosis of small-fiber neuropathy is not met.

    • Painful sensory neuropathy symptoms must be present.
    • There must be no history of a disorder known to predispose to painful neuropathy.
    • Examination must show no evidence consistent with large-fiber neuropathy.
    • Electromyography and nerve-conduction studies must be normal, with no evidence of large-fiber neuropathy.
    Denial Risk

    Sweat gland nerve fiber density is excluded

    Measurement of sweat gland nerve fiber density does not meet coverage criteria. Do not submit this measurement as covered epidermal nerve fiber density testing under this policy.

    Clinical Background

    Nerve fiber density testing analyzes skin biopsy tissue stained with protein gene product 9.5 (PGP 9.5) to evaluate the number and morphology of axons within the epidermis. This assessment supports evaluation of small-fiber sensory neuropathy, which may be present even when standard electrophysiologic testing is normal.

    Definitions and Abbreviations

    Definitions
    AbbreviationENFD
    MeaningEpidermal nerve fiber density
    Measurement contextThe density of nerve fibers within the epidermis, evaluated as part of nerve fiber density testing
    Definitions
    AbbreviationSFN
    MeaningSmall fiber neuropathy
    Clinical contextA disorder involving small sensory and/or autonomic nerve fibers; skin biopsy may be used in its diagnostic evaluation
    Policy Summary
    PayerPresbyterian Health Plan
    PolicyNerve Fiber Density Testing
    Policy CodePolicy N/A
    Change TypeNon-material revision
    Effective DateJun 1, 2026
    Next Review DateN/A
    Key ActionVerify that all four coverage criteria are met before requesting epidermal nerve fiber density measurement for small-fiber neuropathy.
    SourceLink
    On This Page
    Coverage CriteriaApplicable Procedure CodesCoverage Exclusions and Denial RisksClinical BackgroundDefinitions and Abbreviations
    Denial Risk

    Use testing only for the covered indication

    Epidermal nerve fiber density measurement from a skin biopsy does not meet coverage criteria for situations other than the specified painful sensory neuropathy presentation with no predisposing disorder, no large-fiber findings, and normal electromyography and nerve-conduction studies.

    • Coverage is limited to the specified diagnosis of small-fiber neuropathy.
    • Testing for other situations or indications is not covered under this policy.
    Definitions
    AbbreviationIENFD
    MeaningIntraepidermal nerve fiber density
    Clinical useA validated skin-biopsy measure used to assess small-fiber involvement, particularly small-fiber sensory neuropathy
    Definitions
    AbbreviationNCS
    MeaningNerve conduction studies
    Policy contextElectrodiagnostic testing used to evaluate large-fiber neuropathy; for covered skin-biopsy testing, nerve-conduction studies must be normal and show no evidence of large-fiber neuropathy
    Definitions
    AbbreviationSGNF
    MeaningSweat gland nerve fiber
    Coverage contextSweat gland nerve fiber density can be examined, but measurement of sweat gland nerve fiber density does not meet the policy’s coverage criteria
    Definitions
    AbbreviationPGP
    MeaningProtein gene product 9.5
    Testing contextA protein marker used in nerve fiber density testing terminology
    Definitions
    DefinitionIENFD is the quantification of nerve fibers within the epidermis from a skin biopsy
    Clinical useIt is used to assess small-fiber involvement and may help confirm the clinical diagnosis of small fiber neuropathy
    Testing contextDistal-leg skin biopsy with quantification of linear IENF density is considered a reliable and efficient technique for assessing small fiber neuropathy
    Definitions
    DefinitionSFN, also called small fiber sensory neuropathy or SFSN, is a neuropathic disorder involving small sensory and/or autonomic nerve fibers
    Diagnostic contextSkin biopsy with IENFD quantification may be considered for diagnosis, particularly in small fiber sensory neuropathy
    Clinical findingsSmall-fiber neuropathy may occur with reduced IENFD even when nerve-conduction studies are normal
    Definitions
    DefinitionThe leg-to-thigh IENF density ratio compares intraepidermal nerve fiber density measured at the leg with density measured at the thigh
    Clinical useThe ratio may help distinguish length-dependent small fiber neuropathy from small-fiber sensory ganglionopathy
    Reported findingsThe ratio was lower in length-dependent SFN than in small-fiber sensory ganglionopathy: 0.44 ± 0.23 versus 0.68 ± 0.28